The members of the Board of Management and Supervisory Board of STRATEC Biomedical AG are required under Section 15a of the German Securities Trading Act (WpHG) to report the purchase or sale of STRATEC shares. In addition to purchases or sales of STRATEC shares, transactions in securities relating to STRATEC shares (e.g. sales or purchases of warrants for STRATEC shares) also have to be reported. Following the enactment of the German Investor Protection Improvement Act (AnSVG) on October 30, 2004, the group of individuals subject to these requirements was extended to include persons who have regular access to insider information and are authorized to make significant corporate decisions. The reporting obligations further apply to securities dealings by natural persons and legal entities closely related to one of the aforementioned persons.
Those directors’ dealings requiring report under Section 15a WpHG which were undertaken in the past 360 days can be viewed here.